Produção Nacional
Revisado por pares
Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review
2019; Sociedade Brasileira de Urologia; Volume: 45; Issue: 3 Linguagem: Inglês
10.1590/s1677-5538.ibju.2018.0798
ISSN1677-6119
AutoresAndré Deeke Sasse, Rodolfo Borges dos Reis, Lucas Nogueira, Fernando Cotait Maluf, Daniel Herchenhorn, Òren Smaletz, Volney Soares Lima, Fabio A.B. Schutz, Diogo Assed Bastos, Evanius Garcia Wiermann, Igor Alexandre Protzner Morbeck, Leonardo Fontes Jardim, Vinícius Carrera Souza, Ícaro Thiago de Carvalho, Elton Trigo Teixeira Leite, Archimedes Nardozza, Antônio Carlos Lima Pompeo, Francisco Flávio Horta Bretas, Marcos Lima de Oliveira Leal, Marcus Vinícius Sadi, José Ricardo Tuma da Ponte, Gustavo Franco Carvalhal,
Tópico(s)Prostate Cancer Diagnosis and Treatment
ResumoProstate cancer is the second most common cancer and the fi fth leading cause of cancer deaths. In Brazil, it is likewise the second most common cancer among men, second only to non-melanoma skin cancers. The aim of this consensus is to align different opinions and interpretations of the medical literature in a practical and patient-oriented approach. The fi rst Brazilian Consensus on the Treatment of Advanced Prostate Cancer was published in 2017, with the goal of reducing the heterogeneity of therapeutic conduct in Brazilian patients with metastatic prostate cancer. We acknowledge that in Brazil the incorporation of different technologies is a big challenge, especially in the Sistema Único de Saúde (SUS), which allows for the disparity in the options available to patients treated in different institutions. In order to update the recommendations and to make them objective and easily accessible, once more a panel of specialists was formed in order to discuss and elaborate a new Brazilian Consensus on Advanced Prostate Cancer. This Consensus was written through a joint initiative of the Brazilian Society of Clinical Oncology (SBOC) and the Brazilian Society of Urology (SBU) to support the clinical decisions of physicians and other health professionals involved in the care of patients with prostate cancer.
Referência(s)